<code id='D2E687BC7C'></code><style id='D2E687BC7C'></style>
    • <acronym id='D2E687BC7C'></acronym>
      <center id='D2E687BC7C'><center id='D2E687BC7C'><tfoot id='D2E687BC7C'></tfoot></center><abbr id='D2E687BC7C'><dir id='D2E687BC7C'><tfoot id='D2E687BC7C'></tfoot><noframes id='D2E687BC7C'>

    • <optgroup id='D2E687BC7C'><strike id='D2E687BC7C'><sup id='D2E687BC7C'></sup></strike><code id='D2E687BC7C'></code></optgroup>
        1. <b id='D2E687BC7C'><label id='D2E687BC7C'><select id='D2E687BC7C'><dt id='D2E687BC7C'><span id='D2E687BC7C'></span></dt></select></label></b><u id='D2E687BC7C'></u>
          <i id='D2E687BC7C'><strike id='D2E687BC7C'><tt id='D2E687BC7C'><pre id='D2E687BC7C'></pre></tt></strike></i>

          Home / comprehensive / knowledge

          knowledge


          knowledge

          author:knowledge    Page View:555
          Adobe

          LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

          The deal includes up to another $400 million in payments if certain milestones are met.

          advertisement

          Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In